Soligenix Inc. Reports Promising Results in HyBryte(TM) Trial for Early-Stage Cutaneous T-Cell Lymphoma

Soligenix Inc. (NASDAQ: SNGX) has announced encouraging interim results from its ongoing investigator-initiated study of HyBryte(TM), a potential breakthrough in the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The study, led by Dr. Ellen Kim, director of the Penn Cutaneous Lymphoma Program, highlights the effectiveness of HyBryte(TM) in patients with early-stage mycosis fungoides, a common type of CTCL. With no new FDA-approved, skin-directed therapies introduced in over a decade, these findings represent a significant advancement in the field.

The interim results, shared in collaboration with the Cutaneous Lymphoma Foundation, reveal that at the 18-week evaluation point, six out of participants showed promising responses to the treatment. HyBryte(TM), a synthetic hypericin, is administered twice weekly for up to 54 weeks, offering a novel approach to managing this challenging condition. The lack of effective treatments for early-stage CTCL patients underscores the importance of this development, as current options often come with significant risks.

Dr. Kim, a leading enroller in Soligenix’s phase 3 FLASH study and principal investigator for the confirmatory phase 3 FLASH2 trial, emphasized the need for alternative treatments. 'With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,' she stated. The success of HyBryte(TM) in these trials could pave the way for its approval and widespread use, providing a much-needed solution for patients and healthcare providers alike.

For more detailed information on the study, visit https://ibn.fm/IUoEe. Investors and interested parties can find the latest updates on Soligenix and its developments in the company’s newsroom at https://ibn.fm/SNGX.